158 related articles for article (PubMed ID: 34538863)
21. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
22. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
[TBL] [Abstract][Full Text] [Related]
23. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
Prakash R; Subbiah V; Iyer SP
Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
[TBL] [Abstract][Full Text] [Related]
24. Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database.
Ma Z; Zhang Y; Zhu M; Feng L; Zhang Y; An Z
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1351-1361. PubMed ID: 36111954
[TBL] [Abstract][Full Text] [Related]
25. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
26. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
27. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
[TBL] [Abstract][Full Text] [Related]
28. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
[TBL] [Abstract][Full Text] [Related]
29. Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis.
Aboukaoud M; Wilf-Yarkoni A; Maor E
Epilepsia; 2023 Sep; 64(9):2322-2329. PubMed ID: 37350356
[TBL] [Abstract][Full Text] [Related]
30. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
31. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
32. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
[TBL] [Abstract][Full Text] [Related]
33. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
[TBL] [Abstract][Full Text] [Related]
34. Site-specific antibody drug conjugates for cancer therapy.
Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
[TBL] [Abstract][Full Text] [Related]
35. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
36. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
[TBL] [Abstract][Full Text] [Related]
37. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
Cianfriglia M
Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
39. [Antibody-drug conjugates: a new therapeutic class?].
Chofflon I; Dietrich PY; Thang NN
Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
[TBL] [Abstract][Full Text] [Related]
40. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
